Proceedings of the National Academy of Sciences of the United States of America, Volumen 103, Issue 41, 2018, Pages 15079-15084
Identifier
dc.identifier.issn
00278424
Identifier
dc.identifier.other
10.1073/pnas.0606845103
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164252
Abstract
dc.description.abstract
Increased expression of casein kinase 2 (CK2) is associated with hyperproliferation and suppression of apoptosis in cancer. Mutations in the tumor suppressor APC (adenomatous polyposis coli) are frequent in colon cancer and often augment β-catenin-T cell factor (Tcf)/lymphoid enhancer binding factor (Lef)-dependent transcription of genes such as c-myc and cyclin-D1. CK2 has also been implicated recently in the regulation of β-catenin stability. To identify mechanisms by which CK2 promotes survival, effects of the specific CK2 inhibitors 4,5,6,7-tetrabromobenzotriazole (TBB) and 2-dimethylamino-4,5,6, 7-tetrabromo-1H-benzimidazole were assessed. TBB and 2-dimethylamino-4,5,6,7- tetrabromo-1H-benzimidazole significantly decreased proliferation and increased apoptosis of HT29(US) colon cancer cells. RT-PCR and immunoblot analysis revealed that both inhibitors decreased survivin mRNA and protein levels in HT29(US) cells. Similar effects were observed with TBB in human DLD-1 and SW-480 colo